Overview

A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Chronic Phase With T315I Mutation

Status:
Active, not recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of HQP1351 in patients with chronic myeloid leukemia in chronic phase (CML-CP) harboring T315I mutation. The efficacy of HQP1351 was determined by evaluating the subjects' major cytogenetic response (MCyR).
Phase:
Phase 2
Details
Lead Sponsor:
Ascentage Pharma Group Inc.